Abrdn Life Sciences Investors (HQL) — SEC Filings
Abrdn Life Sciences Investors (HQL) — 8 SEC filings. Latest: DEF 14A (Apr 14, 2025). Includes 5 SC 13D/A, 2 DEF 14A, 1 DEFA14A.
View Abrdn Life Sciences Investors on SEC EDGAR
Overview
Abrdn Life Sciences Investors (HQL) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a DEF 14A filed on Apr 14, 2025: abrdn Life Sciences Investors (formerly Tekla World Healthcare Fund) filed a DEF 14A on April 14, 2025, for the period ending May 28, 2025. The filing pertains to abrdn Healthcare Opportunities Fund and abrdn Healthcare Investors, both located at 1900 Market Street, Philadelphia, PA. These entities
Sentiment Summary
Across 8 filings, the sentiment breakdown is: 8 neutral. The dominant filing sentiment for Abrdn Life Sciences Investors is neutral.
Filing Type Overview
Abrdn Life Sciences Investors (HQL) has filed 2 DEF 14A, 5 SC 13D/A, 1 DEFA14A with the SEC between Jan 2024 to Apr 2025.
Filings by Year
Recent SEC Filings (8)
| Date | Form | Description | Risk |
|---|---|---|---|
| Apr 14, 2025 | DEF 14A | abrdn Life Sciences Investors DEF 14A Filing | low |
| Jun 3, 2024 | SC 13D/A | Saba Capital Management Amends 13D Filing for abrdn Life Sciences | medium |
| May 24, 2024 | DEFA14A | abrdn Life Sciences Investors files proxy materials | low |
| Apr 29, 2024 | SC 13D/A | Saba Capital Management Amends abrdn Life Sciences Investors Filing | medium |
| Apr 22, 2024 | DEF 14A | abrdn Life Sciences Investors Announces Annual Meeting of Shareholders | low |
| Apr 17, 2024 | SC 13D/A | Saba Capital Management Amends 13D Filing for abrdn Life Sciences | medium |
| Feb 7, 2024 | SC 13D/A | Saba Capital Amends abrdn Life Sciences Investors Stake | |
| Jan 12, 2024 | SC 13D/A | Saba Capital Amends abrdn Life Sciences Investors (HQL) 13D Filing |
Risk Profile
Risk Assessment: Of HQL's 6 recent filings, 0 were flagged as high-risk, 3 as medium-risk, and 3 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Key Executives
- Boaz R. Weinstein
- BOAZ R. WEINSTEIN
Industry Context
abrdn Life Sciences Investors is a closed-end investment company. This filing pertains to its annual shareholder meeting and governance matters.
Top Tags
amendment (4) · sec-filing (2) · activism (2) · activist-investing (2) · proxy-statement (1) · governance (1) · fund-filing (1) · ownership-filing (1) · proxy-filing (1) · administrative (1)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Accession Number | 0001062993-24-011603 | Unique identifier for the SEC filing |
| Filing Date | 20240603 | Date the amendment was filed with the SEC |
| Amendment Number | 4 | This is the fourth amendment to the filing. |
| Annual Meeting Date | June 25, 2024 | Date of the annual meeting of shareholders. |
| Record Date | April 1, 2024 | Shareholders of record on this date are entitled to vote. |
| Trustee Term End | 2027 | Year until which elected Class B Trustees will serve. |
Frequently Asked Questions
What are the latest SEC filings for Abrdn Life Sciences Investors (HQL)?
Abrdn Life Sciences Investors has 8 recent SEC filings from Jan 2024 to Apr 2025, including 5 SC 13D/A, 2 DEF 14A, 1 DEFA14A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of HQL filings?
Across 8 filings, the sentiment breakdown is: 8 neutral. The dominant sentiment is neutral.
Where can I find Abrdn Life Sciences Investors SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Abrdn Life Sciences Investors (HQL) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Abrdn Life Sciences Investors?
Financial highlights for Abrdn Life Sciences Investors are available when 10-K or 10-Q filings are enriched with AI analysis. Check back as new filings are processed.
What is the investment thesis for HQL?
The investment thesis for HQL includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Abrdn Life Sciences Investors?
Key executives identified across Abrdn Life Sciences Investors's filings include Boaz R. Weinstein, BOAZ R. WEINSTEIN.
What are the main risk factors for Abrdn Life Sciences Investors stock?
Of HQL's 6 assessed filings, 0 were flagged high-risk, 3 medium-risk, and 3 low-risk.
What are recent predictions and forward guidance from Abrdn Life Sciences Investors?
Forward guidance and predictions for Abrdn Life Sciences Investors are extracted from SEC filings as they are enriched.